S&P 500 7,722.60 ▲ 45.83 (+0.60%) DOW 52,377.57 ▲ 15.97 (+0.03%) NASDAQ 26,477.81 ▲ 308.43 (+1.18%) US Markets Closed â€ĸ 02:06 AM ET

KRSA

Korsana Biosciences, Inc.

Price Chart
Latest Quote

$30.07

-2.02 (-6.29%)
Current Price
Previous Close $32.09
Open $31.81
Day High $32.26
Day Low $29.50
Volume 196,731
Fetched: 2026-10-28T06:05:59
Stock Information
Shares Outstanding 45.54M
Total Debt $1.10M
Cash Equivalents $134.16M
Net Income $-49.08M
Sector Healthcare
Industry Biotechnology
Market Cap $1.37B
EPS (TTM) $-7.07
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$222.89M
Income$-49.08M
Book/sh$-7.84
Cash/sh$2.95
Employees19
Financial Ratios
Quick Ratio17.28
Current Ratio17.40
Debt/Eq0.85
Returns & Margins
Ownership
Insider Ownership6.64%
Institutional Ownership45.26%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-8.46
P/B-3.84
Analyst Data
Recommendationnone
Target Price$44.00
Technical Indicators
SMA20$32.16
SMA50$31.00
SMA200$21.66
RSI45.62
ATR2.6768
Shares Float4.31M
Short Ratio0.14
Volatility1.73
Rel Volume1.39
Performance History
Week-3.09%
Month-2.47%
Quarter+22.73%
6 Months+41.31%
YTD+220.58%
Year+102.63%
3 Years+32.58%
5 Years-91.93%
10 Years-98.28%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-10-27 $30.07 196,700
2026-10-26 $32.09 230,500
2026-10-23 $31.31 402,000
2026-10-22 $33.43 93,100
2026-10-21 $32.54 129,800
2026-10-20 $31.03 105,800
2026-10-19 $31.41 346,100
2026-10-16 $32.38 112,900
2026-10-15 $33.65 176,000
2026-10-14 $34.32 193,600
2026-10-13 $31.66 170,600
2026-10-12 $34.04 59,200
2026-10-09 $33.92 45,900
2026-10-08 $33.51 194,100
2026-10-07 $31.65 37,100
2026-10-06 $31.77 42,000
2026-10-05 $30.72 104,300
2026-10-02 $30.49 51,700
2026-10-01 $31.20 14,700
2026-09-30 $32.00 121,100
2026-09-29 $34.00 96,900
2026-09-28 $30.83 51,500
About Korsana Biosciences, Inc.

Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes. The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases. Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.

📰 Latest News
No news articles available at the moment. Check back later for updates on KRSA.
Period:
Income Statement (Annual)
Metric 2025-12-31 2024-12-31
Revenue
Total Revenue $0 $0
Operating Revenue $0 $0
Expenses
Total Expenses $37,291,000 $109,000
Net Non Operating Interest Income Expense $1,649,000 $21,000
Operating Expense $37,291,000 $109,000
General And Administrative Expense $4,506,000 $53,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-35,642,000 $-88,000
Net Interest Income $1,649,000 $21,000
Interest Income $1,649,000 $21,000
Normalized Income $-35,642,000 $-88,000
Net Income From Continuing And Discontinued Operation $-35,642,000 $-88,000
Total Operating Income As Reported $-37,291,000 $-109,000
Net Income Common Stockholders $-35,642,000 $-88,000
Net Income $-35,642,000 $-88,000
Net Income Including Noncontrolling Interests $-35,642,000 $-88,000
Net Income Continuous Operations $-35,642,000 $-88,000
Pretax Income $-35,642,000 $-88,000
Interest Income Non Operating $1,649,000 $21,000
Operating Income $-37,291,000 $-109,000
Per Share
Diluted EPS - $-0.02
Basic EPS - $-0.02
Other
Tax Effect Of Unusual Items $0 $0
Tax Rate For Calcs $0 $0
Normalized EBITDA (Bullshit earnings) $-37,291,000 $-109,000
EBITDA (Bullshit earnings) $-37,291,000 $-109,000
EBIT $-37,291,000 $-109,000
Diluted NI Availto Com Stockholders $-35,642,000 $-88,000
Research And Development $32,785,000 $56,000
Selling General And Administration $4,506,000 $53,000
Other Gand A $3,232,000 $53,000
Salaries And Wages $1,274,000 $0
Diluted Average Shares - $5,041,436
Basic Average Shares - $5,041,436
Fetched: 2026-10-27
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31
Assets
Net Tangible Assets $-33,968,000 $66,000
Total Assets $154,596,000 $10,108,000
Total Non Current Assets $0 $0
Current Assets $154,596,000 $10,108,000
Other Current Assets $461,000 -
Cash Cash Equivalents And Short Term Investments $154,135,000 $10,108,000
Cash And Cash Equivalents $154,135,000 $10,108,000
Liabilities
Total Liabilities Net Minority Interest $188,564,000 $10,042,000
Total Non Current Liabilities Net Minority Interest $176,075,000 $9,964,000
Current Liabilities $12,489,000 $78,000
Payables And Accrued Expenses $12,118,000 $78,000
Payables $176,000 $68,000
Accounts Payable $176,000 $68,000
Equity
Common Stock Equity $-33,968,000 $66,000
Total Equity Gross Minority Interest $-33,968,000 $66,000
Stockholders Equity $-33,968,000 $66,000
Retained Earnings $-35,730,000 $-88,000
Preferred Securities Outside Stock Equity $175,537,000 $9,964,000
Other
Ordinary Shares Number $45,541,425 $45,541,425
Share Issued $45,541,425 $45,541,425
Tangible Book Value $-33,968,000 $66,000
Invested Capital $-33,968,000 $66,000
Working Capital $142,107,000 $10,030,000
Total Capitalization $-33,968,000 $66,000
Additional Paid In Capital $1,761,000 $153,000
Capital Stock $1,000 $1,000
Common Stock $1,000 $1,000
Non Current Accrued Expenses $538,000 $0
Pensionand Other Post Retirement Benefit Plans Current $371,000 $0
Current Accrued Expenses $11,942,000 $10,000
Fetched: 2026-10-27
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31
Free Cash Flow
Free Cash Flow $-22,406,000 $44,000
Operating Activities
Operating Cash Flow $-22,406,000 $44,000
Cash Flow From Continuing Operating Activities $-22,406,000 $44,000
Financing Activities
Issuance Of Capital Stock $165,573,000 $9,964,000
Financing Cash Flow $166,433,000 $10,064,000
Cash Flow From Continuing Financing Activities $166,433,000 $10,064,000
Net Preferred Stock Issuance $165,573,000 $9,964,000
Preferred Stock Issuance $165,573,000 $9,964,000
Other
End Cash Position $154,135,000 $10,108,000
Beginning Cash Position $10,108,000 $0
Changes In Cash $144,027,000 $10,108,000
Proceeds From Stock Option Exercised $860,000 $100,000
Change In Working Capital $11,628,000 $78,000
Change In Payables And Accrued Expense $12,089,000 $78,000
Change In Accrued Expense $11,981,000 $10,000
Change In Payable $108,000 $68,000
Change In Account Payable $108,000 $68,000
Change In Prepaid Assets $-461,000 $0
Stock Based Compensation $1,608,000 $54,000
Net Income From Continuing Operations $-35,642,000 $-88,000
Fetched: 2026-10-27